Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireProductiveAssets.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Increase in deferred revenue | 10,793 | — |
| Net cash provided by operating activities | 42,551 | 13,785 |
| Cash flows from investing activities: | ||
| Acquisitions of property and equipment | (612) | (322) |
| Purchases of investments | (135,635) | (78,103) |
| Sales and maturities of investments | 246,931 | 134,647 |
| Acquisition of Astria Therapeutics, Inc., net of cash acquired | (489,480) | — |
| Net cash (used in) provided by investing activities | (378,796) | 56,222 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's capex?
- BioCryst Pharmaceuticals (BCRX) reported capex of $209K in Q2 2026.
- How has BioCryst Pharmaceuticals's capex changed year-over-year?
- BioCryst Pharmaceuticals's capex increased by 16.8% year-over-year, from $179K to $209K.
- What is the long-term trend for BioCryst Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's capex has grown at a 0.9% compound annual growth rate (CAGR), from $2.39M to $2.47M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about BioCryst Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude